3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
14
Phase 3
3
Phase 1
1
Status
Recruiting
2
Active not recruiting
1
Sponsor Class
OTHER_GOV
1
OTHER
1
INDUSTRY
1
Study Type
Interventional
3
Sponsor
Cancer Type
Gastrointestinal
198
Breast
130
Head & Neck
22
Tumor-Agnostic
4
NET
3
Endocrine
3
CNS
2
Thoracic
1
Other solid neoplasm
1
Other neoplasm
1
Gynecologic
1
Genitourinary
1
Conditions
Neuroendocrine Tumors
3
Gastro-enteropancreatic neuroendocrine tumor
1
Interventions
Everolimus
8
lanreotide
7
Octreotide
7
lutetium Lu 177 dotatate
6
pasireotide
5
Thyrotropin Alfa
5
Mitotane
4
Etoposide
4
Doxorubicin
4
177Lu-octreotide, DOTA(0)-Tyr(3)-
4
amino-acid, glucose, and electrolyte solution
3
Mifepristone
3
Filgrastim
3
Corlux
3
Cisplatin
3
Chemotherapy, Adjuvant
3
Capecitabine
3
Cabergoline
3
vandetanib
2
telotristat ethyl
2
surufatinib
2
ribociclib
2
fluorodopa F 18
2
cabozantinib
2
Temozolomide
2
Receptor-Like Protein Tyrosine Phosphatases, Class 2
2
Lutetium-177
2
Lutetium
2
Leucovorin
2
Iodine-131
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 3
×
Capecitabine
×
Endocrine
×
Clear all
NCT07185672
2025-09-22
PReCedeNT
Tata Memorial Hospital
Phase 3
Recruiting
162 enrolled
NCT04919226
2025-09-10
COMPOSE
ITM Solucin GmbH
Phase 3
Active not recruiting
259 enrolled
NCT05387603
2025-09-10
START-NET
Lund University Hospital
Phase 3
Recruiting
300 enrolled